2017 Fiscal Year Final Research Report
A new therapy for allergic rhinitis using liposome and NKT cell-mediated immunity system
| Project/Area Number |
15K10778
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
Yonekura Syuji 千葉大学, 医学部附属病院, 助教 (20400939)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | アレルギー性鼻炎 / ＮＫＴ細胞 / Ｌｉｐｏｓｏｍｅ / α-Galactosylceramide |
|---|
| Outline of Final Research Achievements |
The efficacy and safety of allergen specific sublingual immunotherapy (SLIT) are established. However, SLIT requires a long administration period of about for three years. I planned the use of the immunoregulation action of the NKT cell for treatment of allergic rhinitis. In this study, I administered ovalbumin (OVA) and liposome including α-GalCer into the oral submucosa of allergic rhinitis mouse model. Administration of OVA/ liposome pulsed α-GalCer suppressed antigen-specific responses. The new therapy for allergic rhinitis using liposome and NKT cell-mediated immunity system may enhance therapeutic efficacy and shorten duration of treatment.
|
| Free Research Field |
アレルギー学
|
